OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
DGQ.ASE55

Delta Gold Technologies PLC

Advanced Medical Equipment & TechnologyVerified

Delta Gold Technologies PLC has a fully diluted share count of 64,644,364 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities at this time. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, which raises uncertainty about its short-term financial stability. The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to compare its performance against industry_config preferred metrics or cohort medians. Without data on return on invested capital (ROIC), operating margins, or net profit margins, it is not possible to assess whether Delta Gold Technologies PLC is generating returns in line with or above industry expectations. Delta Gold Technologies PLC's revenue concentration by segment and geography is not disclosed in the available data, limiting the ability to evaluate its exposure to specific markets or product lines. This lack of transparency could obscure potential vulnerabilities in its business model, such as overreliance on a single geographic region or a narrow set of products. The company's growth trajectory is also unclear, as no numeric deltas or revenue history are provided in the outlook. Without forward-looking guidance or historical performance data, it is difficult to determine whether Delta Gold Technologies PLC is on a path of expansion or contraction. The risk assessment indicates a low level of dilution risk, as there is no evidence of near-term share issuance or convertible instruments that could dilute existing shareholders. However, the absence of liquidity data and the lack of going-concern language in source documents suggest that the company may face financial challenges that are not yet fully disclosed. No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic direction or operational developments. This lack of recent information limits the ability to assess any material changes in the company's business or financial condition.

30-day price · DAL+5.20 (+8.0%)
Low$60.30High$77.05Close$70.50As of18 May, 00:00 UTC
Profile
CompanyDelta Gold Technologies PLC
TickerDGQ.ASE
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Delta Gold Technologies PLC develops and distributes advanced medical equipment and technology solutions within the healthcare sector, primarily generating revenue through the sale and servicing of its medical devices.

Classification. Delta Gold Technologies PLC is classified under the Healthcare economic sector, within the Healthcare Services & Equipment business sector, and the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Delta Gold Technologies PLC has a fully diluted share count of 64,644,364 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities at this time. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, which raises uncertainty about its short-term financial stability. The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to compare its performance against industry_config preferred metrics or cohort medians. Without data on return on invested capital (ROIC), operating margins, or net profit margins, it is not possible to assess whether Delta Gold Technologies PLC is generating returns in line with or above industry expectations. Delta Gold Technologies PLC's revenue concentration by segment and geography is not disclosed in the available data, limiting the ability to evaluate its exposure to specific markets or product lines. This lack of transparency could obscure potential vulnerabilities in its business model, such as overreliance on a single geographic region or a narrow set of products. The company's growth trajectory is also unclear, as no numeric deltas or revenue history are provided in the outlook. Without forward-looking guidance or historical performance data, it is difficult to determine whether Delta Gold Technologies PLC is on a path of expansion or contraction. The risk assessment indicates a low level of dilution risk, as there is no evidence of near-term share issuance or convertible instruments that could dilute existing shareholders. However, the absence of liquidity data and the lack of going-concern language in source documents suggest that the company may face financial challenges that are not yet fully disclosed. No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic direction or operational developments. This lack of recent information limits the ability to assess any material changes in the company's business or financial condition.
Key takeaways
  • Delta Gold Technologies PLC operates in the Advanced Medical Equipment & Technology industry with a high classification confidence of 0.92.
  • The company has no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities.
  • Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
  • Profitability and return metrics are not available, making it difficult to compare the company's performance against industry benchmarks.
  • Revenue concentration by segment and geography is not disclosed, limiting visibility into the company's market exposure.
  • No recent events or forward-looking guidance are available to assess the company's growth trajectory or strategic direction.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyGBP
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4
FY-3
FY-2
FY-1
FY0$0.00
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4
FY-3
FY-2
FY-1
FY0
PeriodOCFCapExFCFSBC
FY-4
FY-3
FY-2
FY-1
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricDGQ.ASEActivity
Op margin-16.5% medp25 -174.5% · p75 8.8%
Net margin-16.5% medp25 -172.4% · p75 8.4%
Gross margin47.4% medp25 34.2% · p75 65.3%
CapEx / revenue-5.4% medp25 -12.5% · p75 -2.2%
Debt / equity4.3% medp25 0.0% · p75 28.0%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 07:58 UTC#5c7bf525
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 18:35 UTCJob: 76bac017